Introduction {#s1}
============

Hypertension (HTN) is a common cause for patient contacts with primary physicians, and there is evidence of suboptimal treatment and inadequate blood pressure control [@pone.0052229-Hajjar1]. In Germany the control status of hypertensive patients in the community [@pone.0052229-Thamm1] and in primary care [@pone.0052229-Sharma1] has been repeatedly and consistently found to be lower in comparison with other European countries and the USA [@pone.0052229-Gasse1], [@pone.0052229-WolfMaier1]. Prompted by these data and because of the medical consequences and economic impact of hypertension, considerable national and international activities targeting improved recognition, treatment and control have been initiated [@pone.0052229-National1], [@pone.0052229-World1]. Against this background, re-examination of the recorded prevalence and control of hypertension is essential to monitor changes that might have occurred as a result of enhanced prevention and treatment activities. Furthermore, a focus on primary care is appropriate, because of the essential role of primary care physicians as gatekeepers for hypertension management in the German health care system [@pone.0052229-Pittrow1].

Patients with hypertension alone have an increased risk for cardiovascular morbidity and mortality [@pone.0052229-National2] and hypertensive patients with DM and/or metabolic syndrome as comorbidities have even an increased risk for cardiovascular morbidity and mortality compared to patients with hypertension alone [@pone.0052229-Adler1], [@pone.0052229-Stamler1]. It has been shown by meta-analyses and different large-scale studies that strict control of risk factors including cardiovascular disease, DM, hyperlipidemia and smoking status in patients with hypertension can effectively reduce cardiovascular mortality among patients with hypertension [@pone.0052229-Mancia1]. A meta-analysis showed that type-2 diabetic patients might benefit more from lower blood pressure goals than non-diabetic patients with hypertension [@pone.0052229-Turnbull1]. Consequently, national and international medical societies have developed clear recommendations and guidelines for hypertension and risk factor management and respective therapeutic targets [@pone.0052229-Zanchetti1]. For example, the Seventh Report of the Joint National Commission on Prevention, Detection, Evaluation and Treatment of High blood pressure guidelines (JNC-7) recommend blood pressure targets with systolic blood pressure levels below 140 mmHg and diastolic blood pressure levels below 90 mmHg, while for patients with comorbidities the blood pressure (BP) recommendation has been set at 130/80 mmHg [@pone.0052229-Mancia1]. In hypertensive patients with DM, tight control of blood pressure is of particular importance and intense non-pharmacological and pharmacological interventions should be implemented to lower blood pressure to below 130/80 mmHg [@pone.0052229-Hackam1]. In contrast to the clear recommendations and guidelines of medical scientific societies, there is increasing evidence for a disparity between scientifically grounded treatment targets and the actual implementation of guidelines by physicians in Germany [@pone.0052229-Janhsen1].

Our analysis compares the results of the DETECT study with 55,518 participants in 2003 for the estimated prevalence rates using different definitions for diagnosis of hypertension and compares treatment and control rates with the results of the Hypertension and Diabetes Risk Screening and Awareness Study (HYDRA) study [@pone.0052229-Sharma1] with 45,125 participants in 2001 and also comparisons with other German and international studies are made. At the same time the determinants of pharmacotherapy and adequate blood pressure control including among high-risk patients with comorbidities are examined. We used the criteria of the JNC 7 guidelines for the classification of the severity of hypertension: normal BP for a systolic BP\<120 mmHg and a diastolic BP\<80 mmHg; prehypertension for a systolic BP between 120 to 139 mmHg and/or diastolic BP between 80 to 89 mmHg; stage 1 hypertension for a systolic BP between 140 and 159 and/or a diastolic BP between 99 and 90 mmHg; stage 2 hypertension for a systolic BP≥160 mmHg and/or a diastolic BP≥100 mmHg. These categories are almost identical to those suggested by the European Society of Hypertension/European Society for Cardiology (ESH/ESC) [@pone.0052229-Mancia1]. If the systolic and diastolic BP would have led to a different categorisation for hypertension the higher category was chosen.

Methods {#s2}
=======

DETECT (**D**iabetes Cardiovascular Risk-**E**valuation: **T**argets and **E**ssential **D**ata for **C**ommitment of **T**reatment) was initiated to estimate the prevalence and comorbidity patterns of primary care patients and to evaluate new strategies for the prevention and early detection of chronic diseases [@pone.0052229-Pieper1], [@pone.0052229-Wittchen1]. The DETECT study was designed to evaluate the impact of characteristics of the patient and the physician on diagnosis, treatment and control of hypertension. It is a large-scale, cross-sectional study with longitudinal follow-up of a subcohort and nationally representative of primary care situation in Germany [@pone.0052229-Sharma1]. Sampling and data collection for the DETECT study were very similar to the HYDRA study and based on a nationwide sample of physicians with primary care functions (medical practitioners, generalists, general internists). More information about the DETECT study can be found on <http://www.detect-studie.de> and about the HYDRA study on <http://www.hydra-studie.de>. HYDRA was a precursor study of DETECT with identical methods of sampling, design and also assessment of hypertension [@pone.0052229-Wittchen2]. All patients consulting a practice for whatever reason on 16^th^ or 18^th^ September 2003 were included in the DETECT study. The sampling was based on 1060 regional segments in Germany (according to the criteria of the Institute for Medical Statistics, Frankfurt am Main, Germany), 7053 primary care physicians being randomly selected as a sample from all 64707 physicians who had been working as primary care physicians in Germany in 2003 [@pone.0052229-Sharma1]. Following a pre-study to determine characteristics of physicians and settings, the cross-sectional baseline study in the year 2003 was based on a sample of 55519 unselected adult patients, who were examined in a total of 3188 nationally representative primary care offices (73% general practitioners and 27% internists). Participating patients completed a standardized questionnaire regarding sociodemographic and lifestyle factors. Physicians completed a standardized questionnaire asking for information about known or newly diagnosed medical conditions and an evaluation of the clinical and therapeutic profiles of the patients. Information about prescribed anti-hypertensive medication and results of the current examination (e.g. blood lipid levels, blood pressure measurements according to the JNC 7 report [@pone.0052229-Chobanian1]) were also provided by the physician. For the analysis baseline data of the DETECT study for the year 2003 were used. Age groups were defined as follows: 18--29, 30--44, 45--59, 60--74 and 75+ years.

Ethics Statement {#s2a}
----------------

The DETECT study was approved by the ethics committee of the Dresden University of Technology (TU Dresden). Written informed consent was received from all participants.

Diagnostic Conventions {#s2b}
----------------------

In order to allow a comparison of the DETECT study specifically with the previous HYDRA study and further related studies in Germany, this paper applies the methods used and described in a previous study for the measurement of prevalence of hypertension [@pone.0052229-Sharma1]. In DETECT, blood pressure measurements were taken in the physicians' offices as routine part of the physical examination and were done by indirect cuff sphygmomanometry after a 10-minute of rest in a sitting position according to the international guidelines [@pone.0052229-Chobanian1]. In both studies (HYDRA and DETECT) blood pressure was only measured once. Prevalence rates of hypertension were examined using the following definitions which has also used in the HYDRA study as precursor study: a) physician's diagnosis of hypertension as coded in the clinical appraisal questionnaire (HTN~doc~); b) physician's diagnosis *or* the patient's self-reported diagnosis of hypertension (HTN~doc,pat~); c) physician's *or* patient's self-reported diagnosis *or* a BP measurement with a systolic BP≥140 mmHg *and/or* a diastolic BP≥90 (HTN~doc,pat,bp~); d) diagnosis according to the National Health and Nutrition Examination Survey (HTN~NHANES~) [@pone.0052229-Burt1], i.e. a measured BP≥140/90 mmHg *or* treatment with antihypertensive drugs, irrespective of the doctor's or patient's self-reported diagnosis. For the estimation of the proportion of diagnosed patients (\<140/90 mmHg) we used the HTN~NHANES~ criterion for defining hypertension [@pone.0052229-Burt1], [@pone.0052229-Burt2]. These patients were defined as treated if they received antihypertensive drugs and the following drug classes were included: ACE inhibitors, AT1-antagonists, beta-blockers, calcium channel blockers and diuretics. These patients were defined as controlled if blood pressure was below 140/90 mmHg.

Cardiovascular Comorbidity {#s2c}
--------------------------

The physicians' questionnaire explicitly asked for the existence of 28 specified medical diagnoses and also allowed for adding further diagnoses. CHD, DM and hyperlipidemia were exclusively defined as physicians' based diagnoses (newly diagnosed or previously known) [@pone.0052229-Wittchen1]. The physicians' questionnaire contained information about previous myocardial infarction and family history of myocardial infarction.

Cardiovascular Risk Factors {#s2d}
---------------------------

The patients' questionnaire contained information about physical activity and smoking status as cardiovascular risk factors. Physical activity was classified as either more than or equal to 2 hours per week versus physical activity with less than 2 hours per week on average (e.g. gardening, cycling, walking or other sports). Smoking status of the participants was defined as use of any tobacco product in the past 4 weeks and categorized as yes/no. BMI was categorized into three groups: \<25 kg/m^2^ (normal), 25 to \<30 kg/m^2^ (overweight) and ≥30 kg/m^2^ (obesity). Waist circumference (WC) was categorized into the following groups: ≤94 cm for males and ≤80 cm for females as not overweight, \>94 cm and ≤102 cm for males and \>80 cm and ≤88 cm for females as pre-obese, \>102 cm for males and 88 cm for females as obese.

Statistical Analyses {#s2e}
--------------------

DETECT study participants were analyzed with respect to socio-demographic, comorbidities and cardiovascular lifestyle risk factors. Gender and age-group specific estimates of prevalence rates of hypertension were determined applying alternative definitions of hypertension in unselected primary care patients. Also the prevalence of hypertension according to JNC 7 categories was analyzed. Determinants associated with pharmacotherapy and adequate BP control of hypertension such as socio-demographic comorbidities and cardiovascular lifestyle risk factors were evaluated using multiple logistic regression. Education in years was included in the models as potentially explanatory factor. The patients were clustered by primary care units and to account for the clustered structure of the data, robust standard errors were estimated by the Huber-White Matrix. Data were weighted for non-response and attrition during the recruitment phase. Categorical data were presented as absolute frequencies (n) and weighted percentages (%w), metric variables by weighted mean and standard deviation. A two-sided alpha-level of 0.05 was chosen as criterion for statistical significance. All statistical analyses were conducted using STATA 11.2 (Stat Corp. 2009, College Station, Texas, USA).

Results {#s3}
=======

[Table 1](#pone-0052229-t001){ref-type="table"} presents descriptive statistics for sociodemographic and baseline variables for the 55,518 participants of the DETECT study in 2003. The average systolic BP was 131.7 mmHg and diastolic BP was 79.9 mmHg. Of the participants of the DETECT study, 12.1% had physician diagnosed DM, 29.5% hyperlipidemia, 14.7% CHD and 4.2% previous myocardial infarction. Physician based diagnosis of hypertension (HTN~doc~) was present in 35.5% of all participants (see [table 2](#pone-0052229-t002){ref-type="table"}). The prevalence rate of physician diagnosed hypertension increased from the youngest age group (18 to 29 years) to the oldest one (75 years and above) from 2.9% from to 62.6%. Physician's diagnosis or the patient's self-reported diagnosis of hypertension (HTN~doc,pat~) showed slightly higher prevalence rates: 41.8% in all participants, 6.4% in the youngest age group and 69.5% in the oldest age group. Physician's or patient's self-reported diagnosis or a BP measurement with a systolic BP≥140 mmHg and/or a diastolic BP≥90 (HTN~doc,pat,bp~) prevalence rates increased to 55.2% in all participants and were 15.4% and 82.1% in the youngest and oldest age group, respectively. Prevalence rates for hypertension diagnosis according to the National Health and Nutrition Examination Survey (HTN~NHANES~) were in a similar range as for HTN~doc,pat,bp~: 56.0% in all participants, 13.3% in the youngest and 86.8% in the oldest age group. Comparing the estimated prevalence rates for HTN~doc~, HTN~doc,pat~, HTN~doc,pat,bp~ and HTN~NHANES,~ the largest differences measured as ratio of 2 estimated prevalence rates were seen in the youngest age group comparing HTN~doc~ and HTN~NHANES~. The biggest percent difference in absolute number was present in the oldest age group comparing HTN~doc~ to HTN~NHANES~. Limitations of the DETECT study exist, because there was only single measurement of blood pressure in a primary care setting done. Some patients have been excluded from the study, because of time restrictions of the physician or no clinical assessment was possible [@pone.0052229-Powers1]. Several measurements are recommended and prevalence of hypertension is dependent from the setting and inclusion criteria of patients [@pone.0052229-Wittchen1].

10.1371/journal.pone.0052229.t001

###### Sample characteristics of DETECT study participants.

![](pone.0052229.t001){#pone-0052229-t001-1}

                                                        Total         Male        Female                    
  -------------------------------------------------- ------------ ------------ ------------ ------ -------- ------
  Age (mean/sd)                                       53.8/17.4    54.5/16.8    53.3/17.8                   
  18--29 years                                          6,031          11         2,249      9.9    3,782    11.7
  30--44 years                                          11,525         21         4,328      19.5   7,197    22.1
  45--59 years                                          13,555        24.3        5,599      24.5   7,956    24.1
  60--74 years                                          17,934        31.9        8,087      35.3   9,847    29.5
  75+ years                                             6,473         11.9        2,416      10.9   4,057    12.6
  Systolic blood pressure, (mean/sd)                  131.7/18.4   133.8/17.3   130.3/19.0                  
  Diastolic blood pressure, (mean/sd)                  79.9/9.9     80.8/9.8    79.2/10.0                   
  Years of schooling, (mean/sd)                        10.1/2.1     10.2/2.2     10.0/2.0                   
  BMI (mean/sd)                                        26.8/5.3     27.3/4.7     26.5/5.6                   
  \<25 kg/m^2^                                          21,520        40.2        7,037      32.1   14,483   45.8
  25--29.9 kg/m^2^                                      20,383        37.3        10,201     45.8   10,182   31.5
  30+ kg/m^2^                                           12,491        22.5        4,986      22.2   7,505    22.7
  WC (mean/sd)                                        93.8/15.6    99.8/13.8    89.7/15.4                   
  ≤94 cm (male) ≤80 cm (female)                         15,595        31.9        6,667      33.6   8,928    30.7
  \>94 cm--≤102 cm (male) \>80 cm--≤88 cm (female)      10,729        21.9        5,245      26.4   5,484    18.9
  \>102 cm (male) \>88 cm (female)                      22,593        46.2        7,930       40    14,663   50.4
  Current smoker                                        13,504        26.1        6,186      29.2   7,318     24
  Physical activity \<2 hours/week                      16,265        34.3        5,902      30.3   10,363   37.2
  *Comorbidities*                                                                                           
  CHD                                                   8,465         14.7        4,127      17.6   4,338    12.8
  Hyperlipidemia                                        16,178        29.5        7,311      32.4   8,867    27.5
  Diabetes mellitus                                     6,895         12.1        3,969      17.2   2,926    8.6
  Myocardial infarction                                 2,326         4.2         1,649      7.3     677     2.1

N = 55,518, %w = weighted percentages; BMI = body mass index in kg/m2.

Number of valid observations: Blood pressure n = 53,337 (96.1%); Years of schooling n = 53,406 (96.2%); Body mass index.

n = 54,393 (98.0%); Waist circumference n = 48,918 (88.1%); Smoking status n = 52,589 (94.7%); Physical activity n = 48,249 (86.9%).

10.1371/journal.pone.0052229.t002

###### Prevalence rates of hypertension by age, sex and type of diagnosis.
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                           no HTN~doc~   HTN~doc~   no HTN~doc/Pat~   HTN~doc/Pat~   no HTN~doc/Pat/bp~   HTN~doc/Pat/bp~   no HTN~NNANES~ ^†^   HTN~NHANES~ ^†^                           
  -------------- -------- ------------- ---------- ----------------- -------------- -------------------- ----------------- -------------------- ----------------- ------ -------- -------- ------
  Total           Total      35,354       20,164         35.5            31,858            23,660              41.8               24,569             30,949        55.2   23,148   30,189   56.0
                  Female     21,539       11,300         33.6            19,667            13,172              39.3               15,701             17,138        51.6   14,969   16,620   52.0
                   Male      13,815       8,864          38.3            12,191            10,488              45.5               8,868              13,811        60.4   8,179    13,569   61.9
  18--29 years    Total       5,854        177            2.9            5,634              397                 6.4               5,099                932         15.4   5,017     771     13.3
                  Female      3,693         89            2.3            3,586              196                 5.0               3,324                458         12.2   3,258     372     10.3
                   Male       2,161         88            4.0            2,048              201                 8.8               1,775                474         20.8   1,759     399     18.3
  30--44 years    Total      10,291       1,234          10.1            9,726             1,799               14.9               8,192               3,333        28.3   8,014    3,056    27.1
                  Female      6,551        646            8.5            6,250              947                12.6               5,499               1,698        23.1   5,369    1,558    22.1
                   Male       3,740        588           12.7            3,476              852                18.8               2,693               1,635        37.0   2,645    1,498    35.5
  45--59 years    Total       9,068       4,487          32.0            8,113             5,442               39.1               5,992               7,563        55.1   5,744    7,291    55.1
                  Female      5,559       2,397          29.0            5,062             2,894               35.3               3,891               4,065        50.3   3,754    3,908    50.2
                   Male       3,509       2,090          36.3            3,051             2,548               44.5               2,101               3,498        61.8   1,990    3,383    62.2
  60--74 years    Total       7,778       10,156         56.0            6,460             11,474              63.5               4,149              13,785        76.7   3,569    13,664   79.0
                  Female      4,294       5,553          55.7            3,590             6,257               63.0               2,321               7,526        76.2   2,104    7,375    77.5
                   Male       3,484       4,603          56.2            2,870             5,217               64.0               1,828               6,259        77.3   1,465    6,289    80.9
  ≥75 years       Total       2,363       4,110          62.6            1,925             4,548               69.5               1,137               5,336        82.1    804     5,407    86.8
                  Female      1,442       2,615          63.3            1,179             2,878               70.0                666                3,391        83.1    484     3,407    87.1
                   Male        921        1,495          61.2             746              1,670               68.8                471                1,945        80.5    320     2,000    86.1

N = 55,518, † N = 53,337 patients with valid blood pressure assessment; %w = weighted percentages HTNdoc: doctor's diagnosis; HTNdoc/pat: doctor's or patient's diagnosis; HTNdoc/pat/bp: doctor's or patient's diagnosis or blood pressure 140/90 mmHg; HTNHANES: blood pressure \>140/90 mmHg or receiving antihypertensive therapy.

The categories of the measured BP values according to the JNC 7 classification are shown in [table 3](#pone-0052229-t003){ref-type="table"} stratified by age and sex. 14.9% of the participants had normal blood pressure, 44.6% prehypertension, 28.8% stage 1 hypertension and 11.6% stage 2 hypertension. The prevalence rates of hypertension stages 1 and 2 increased together with age. In participants between age 18 and 29 prevalence rates were 10.2% and 1.8%, in patients above 75 years of age prevalence rates were 41.2% and 18.7%, respectively. The mean systolic BP increased continuously with age up to 140.6 mmHg in participants above 75 years of age and diastolic BP increased up to 81.6 mmHg in the age group 60--74 years, but decreased to 79.9 mmHg again in the oldest age group.

10.1371/journal.pone.0052229.t003

###### Prevalence of JNC 7 Blood Pressure Categories.

![](pone.0052229.t003){#pone-0052229-t003-3}

                                                    BP\<120/80 mmHg   BP 120--139/80--89 mmHg   BP 140--159/90--99 mmHg   BP≥160/100 mmHg                          
  --------------------------------------- -------- ----------------- ------------------------- ------------------------- ----------------- -------- ------ ------- ------
  Total[†](#nt105){ref-type="table-fn"}    Total         7,839                 14.9                     23,890                 44.6         15,489   28.8   6,119   11.6
                                           Female        5,729                 18.5                     13,894                 43.8         8,486    26.6   3,480   11.2
                                            Male         2,110                  9.8                      9,996                 45.8         7,003    32.1   2,639   12.3
  18--29 years                             Total         2,114                 36.8                      2,982                 51.3          584     10.2    108    1.8
                                           Female        1,608                 44.7                      1,699                 46.2          284     8.0     39     1.0
                                            Male          506                  23.1                      1,283                 59.9          300     13.8    69     3.2
  30--44 years                             Total         2,681                 24.6                      5,882                 52.9         1,935    17.3    572    5.2
                                           Female        2,155                 31.5                      3,539                 50.9          975     13.9    258    3.7
                                            Male          526                  13.1                      2,343                 56.3          960     22.9    314    7.7
  45--59 years                             Total         1,630                 12.8                      6,089                 46.6         3,880    29.5   1,436   11.1
                                           Female        1,216                 16.2                      3,623                 47.2         2,091    27.0    732    9.6
                                            Male          414                   7.9                      2,466                 45.9         1,789    33.0    704    13.2
  60--74 years                             Total         1,081                  6.3                      6,768                 39.1         6,519    37.7   2,865   17.0
                                           Female         583                   6.2                      3,723                 39.2         3,518    36.8   1,655   17.8
                                            Male          498                   6.5                      3,045                 38.9         3,001    38.8   1,210   15.9
  ≥75 years                                Total          333                   5.4                      2,169                 34.8         2,571    41.2   1,138   18.7
                                           Female         167                   4.3                      1,310                 33.6         1,618    41.1    796    21.0
                                            Male          166                   7.2                       859                  36.7          953     41.3    342    14.8

N = 53,337 patients with valid blood pressure assessment; %w = weighted percentages; BP = blood pressure.

Diagnosis, Treatment and Control Rates in the DETECT Study {#s3a}
----------------------------------------------------------

Across all age groups 61.5% of HTN~NHANES~ cases were diagnosed (coded in the clinical appraisal) by the physicians. In the youngest there was the smallest proportion of diagnosed HTN~NHANES~ cases (17.4% only). In the age group 75+ the fraction of physician diagnosed cases was highest (71.0%). The rates of HTN~NHANES~ cases, which were diagnosed and also treated by physicians increased with higher age: 12.1% in the youngest age group and 65.7% in the oldest age group. Among HTN~NHANES~ cases the proportion of patients with adequate blood pressure control was 21.4% across all groups; it was 5.8% in the youngest and 23.3% in the oldest age group.

Comparison between HYDRA and DETECT Study {#s3b}
-----------------------------------------

The comparison presented in [figure 1](#pone-0052229-g001){ref-type="fig"} reveals that the proportion of diagnosed patients was lower in the DETECT study in comparison to the HYDRA study. These changes are consistent, and are significant (p\<0.05) in all age groups above age 30 for men and women. The comparison between these studies shows also indications of, albeit small, improvements in rates of treated and controlled hypertension. The changes are consistent, although not significant in all gender and age group comparisons. Significant improvements (p\<0.05) in the rates of treatment were found in females 30--44 years of age and in males 30--44 and 45--59 years of age. Rates of antihypertensive drug therapy decreased significantly in male patients aged 75 years and older. Adequate BP control was significantly more common in older female patients (age group 60+ years).

![Diagnosis, treatment and control rates among NHANES hypertension cases in DETECT and HYDRA study.\
Comparison between DETECT study (N = 30189) and HYDRA study (N = 22744) for diagnosis, treatment and control rates. Diagnosed = diagnosed by physician among NHANES cases; diagnosed+treated = diagnosed by physician and treated by antihypertensive drugs among NHANES cases; diagnosed+treated+controlled = diagnosed by physician, treated by antihypertensive drugs and blood pressure \<140/90 mmHg among NHANES cases. A comparison between both studies reveals that the proportion of diagnosed patients among NHANES hypertension cases was lower in the first study for all age groups above age 30 for men and women (p\<0.05). Small (significant) improvements in rates of diagnosed and treated hypertension were found in females 30--44 years of age and in males 30--44 and 45--59 years of age (p\<0.05). Small (significant) improvements in rates of diagnosed, treated and controlled hypertension were found in females 60--64 years of age and in males 30--44 and 45--59 years of age (p\<0.05).](pone.0052229.g001){#pone-0052229-g001}

Factors Associated with Pharmacotherapy {#s3c}
---------------------------------------

[Table 4](#pone-0052229-t004){ref-type="table"} shows factors associated with pharmacotherapy for hypertension. Patients in the oldest age group were approximately tenfold more likely to take antihypertensive drugs (OR 10.58, 95%-CI 8.36--13.39). Further factors associated with receiving antihypertensive medication in NHANES based cases were female sex (OR 1.18, 95%-CI 1.10--1.27), BMI above 30 kg/m^2^ (OR 1.72, 95%-CI 1.57--1.89), a history of CHD (OR 4.64, 95%-CI 3.92--5.50), a physician based diagnosis of hyperlipidemia (OR 1.66, 95%-CI 1.54--1.79), DM (OR 1.98, 95%-CI 1.79--2.19) or previous myocardial infarction (OR 2.27, 95%-CI 1.60--3.21). An alternative specification with waist circumference (reference category: not overweight) instead of BMI as a measure of cardiovascular risk gave very similar results. Smoking was negatively associated with receiving antihypertensive medication (OR 0.79, 95%-CI 0.72--0.86).

10.1371/journal.pone.0052229.t004

###### Determinants of pharmacotherapy among NHANES hypertension cases.
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                                                                            Antihypertensive treatment (N = 21,323)                                                                                                                                           
  --------------------------------------------------------------- -------- ----------------------------------------- --------------------------------------- ---------------------------------------- -------------- ---------------------------------------- -------------
  Male gender                                                      12,941                    9,464                                    72.3                                 (reference)                 (reference)                                            
  Female gender                                                    15,876                   11,859                                    73.9                    1.08[\*](#nt109){ref-type="table-fn"}     1.02--1.14    1.18[\*](#nt109){ref-type="table-fn"}    1.10--1.27
  *Age in years*                                                                                                                                                                                                                                              
  18--29                                                            682                       146                                      20                                  (reference)                 (reference)                                            
  30--44                                                           2,811                     1,194                                    40.8                    2.75[\*](#nt109){ref-type="table-fn"}     2.24--3.39    2.08[\*](#nt109){ref-type="table-fn"}    1.67--2.59
  45--59                                                           6,903                     4,604                                    65.6                    7.62[\*](#nt109){ref-type="table-fn"}     6.24--9.30    4.57[\*](#nt109){ref-type="table-fn"}    3.70--5.65
  60--74                                                           13,202                   10,827                                    81.4                    17.57[\*](#nt109){ref-type="table-fn"}   14.42--21.40   8.19[\*](#nt109){ref-type="table-fn"}    6.61--10.16
  ≥75                                                              5,219                     4,552                                    86.5                    25.68[\*](#nt109){ref-type="table-fn"}   20.81--31.68   10.58[\*](#nt109){ref-type="table-fn"}   8.36--13.39
  Years of schooling, (mean/sd)[‡](#nt110){ref-type="table-fn"}                             9.4/2.0                   0.87[\*](#nt109){ref-type="table-fn"}                 0.86--0.88                     0.98                     0.97--1.00                
  *BMI*                                                                                                                                                                                                                                                       
  \<25 kg/m^2^                                                     7,095                     4,745                                    66.3                                 (reference)                 (reference)                                            
  25--29.9 kg/m^2^                                                 12,169                    9,008                                    73.4                    1.41[\*](#nt109){ref-type="table-fn"}     1.32--1.51    1.24[\*](#nt109){ref-type="table-fn"}    1.14--1.35
  30+ kg/m^2^                                                      9,186                     7,283                                    78.2                    1.82[\*](#nt109){ref-type="table-fn"}     1.69--1.96    1.72[\*](#nt109){ref-type="table-fn"}    1.57--1.89
  Current non-smoker                                               22,809                   17,536                                    76.1                                 (reference)                 (reference)                                            
  Current smoker                                                   4,912                     2,952                                    59.6                    0.46[\*](#nt109){ref-type="table-fn"}     0.43--0.50    0.79[\*](#nt109){ref-type="table-fn"}    0.72--0.86
  Physical activity ≥2 hours/week                                  16,422                   12,025                                    72.2                                 (reference)                 (reference)                                            
  Physical activity \<2 hours/week                                 7,903                     5,660                                    70.9                    0.94[\*](#nt109){ref-type="table-fn"}     0.88--1.00                     1.02                    0.94--1.09
  *Comorbidities*                                                                                                                                                                                                                                             
  no CHD                                                           22,829                   15,639                                    67.6                                 (reference)                 (reference)                                            
  CHD                                                              5,988                     5,684                                    94.9                    8.83[\*](#nt109){ref-type="table-fn"}     7.80--9.99    4.64[\*](#nt109){ref-type="table-fn"}    3.92--5.50
  no Hyperlipidemia                                                16,825                   11,274                                    65.8                                 (reference)                 (reference)                                            
  Hyperlipidemia                                                   11,992                   10,049                                    83.2                    2.56[\*](#nt109){ref-type="table-fn"}     2.41--2.72    1.66[\*](#nt109){ref-type="table-fn"}    1.54--1.79
  no Diabetes mellitus                                             21,814                   15,144                                    68.6                                 (reference)                 (reference)                                            
  Diabetes mellitus                                                7,003                     6,179                                    87.8                    3.28[\*](#nt109){ref-type="table-fn"}     3.02--3.56    1.98[\*](#nt109){ref-type="table-fn"}    1.79--2.19
  no Myocardial infarction                                         26,719                   19,287                                    71.3                                 (reference)                 (reference)                                            
  Myocardial infarction                                            2,098                     2,036                                    96.9                    12.66[\*](#nt109){ref-type="table-fn"}   9.73--16.47    2.27[\*](#nt109){ref-type="table-fn"}    1.60--3.21

N = 30,189; %w = weighted percentages; OR = Odds Ratio estimated by logistic regression; 95% CI = 95% confidence interval.

unadjusted OR;

adjusted OR from multivariate analyses;

significant on 5% level.

OR for increase of 1 year.

Factors Associated with Blood Pressure Control {#s3d}
----------------------------------------------

In HTN~doc~ cases, the factors associated with adequate blood pressure control (less than 140/90 mmHg) were female sex (OR 1.16, 95%-CI 1.07--1.25), the presence of CHD (OR 1.25, 95%-CI 1.13--1.39), previous myocardial infarction (OR 1.76, 95%-CI 1.50--2.05) and antihypertensive medication (OR 1.41, 95%-CI 1.23--1.61) ([table 5](#pone-0052229-t005){ref-type="table"}). With increasing age the likelihood of adequate blood pressure control was reduced (OR 0.57, 95%-CI 0.39--0.82 for the highest age group) and also for a BMI above 30 kg/m^2^ (OR 0.67, 95%-CI 0.61--0.74). An alternative specification with waist circumference (reference category: not overweight) instead of BMI as a measure of cardiovascular risk gave also very similar results in this regression. Comorbidities (hyperlipidemia, DM and lifestyle factors) such as physical activity and smoking status) had no effect on blood pressure control.

10.1371/journal.pone.0052229.t005

###### Determinants of adequate blood pressure control among physician diagnosed hypertension cases.

![](pone.0052229.t005){#pone-0052229-t005-5}

                                                                            Adequate blood pressure control (N = 6989)                                                                                                                                        
  --------------------------------------------------------------- -------- -------------------------------------------- --------------------------------------- --------------------------------------- ------------- --------------------------------------- ------------
  Male gender                                                      8,570                      3,085                                      35.5                                 (reference)                (reference)                                          
  Female gender                                                    10,959                     3,904                                      35.3                                    0.99                    0.93--1.05    1.16[\*](#nt114){ref-type="table-fn"}   1.07--1.25
  *Age in years*                                                                                                                                                                                                                                              
  18--29                                                            168                         77                                       45.3                                 (reference)                (reference)                                          
  30--44                                                           1,187                       465                                       38.7                                    0.76                    0.54--1.07                    0.88                    0.61--1.28
  45--59                                                           4,337                      1,619                                      36.8                    0.71[\*](#nt114){ref-type="table-fn"}   0.51--0.98                    0.76                    0.53--1.08
  60--74                                                           9,841                      3,491                                      35.2                    0.66[\*](#nt114){ref-type="table-fn"}   0.48--0.90    0.66[\*](#nt114){ref-type="table-fn"}   0.47--0.95
  ≥75                                                              3,996                      1,337                                       33                     0.60[\*](#nt114){ref-type="table-fn"}   0.43--0.83    0.57[\*](#nt114){ref-type="table-fn"}   0.39--0.82
  Years of schooling, (mean/sd)[‡](#nt115){ref-type="table-fn"}                              9.4/2.0                     1.03[\*](#nt114){ref-type="table-fn"}                1.01--1.04                    1.01                    1.00--1.03                
  *BMI*                                                                                                                                                                                                                                                       
  \<25 kg/m^2^                                                     4,035                      1,639                                      40.6                                 (reference)                (reference)                                          
  25--29.9 kg/m^2^                                                 8,200                      3,027                                      36.3                    0.83[\*](#nt114){ref-type="table-fn"}   0.77--0.90    0.85[\*](#nt114){ref-type="table-fn"}   0.77--0.93
  30+ kg/m^2^                                                      7,019                      2,237                                      31.4                    0.67[\*](#nt114){ref-type="table-fn"}   0.61--0.73    0.64[\*](#nt114){ref-type="table-fn"}   0.57--0.70
  Current non-smoker                                               15,881                     5,689                                      35.3                                 (reference)                (reference)                                          
  Current smoker                                                   2,752                      1,005                                      36.5                                    1.05                    0.96--1.15                    0.98                    0.88--1.09
  Physical activity ≥2 hours/week                                  10,883                     4,017                                      36.5                                 (reference)                (reference)                                          
  Physical activity \<2 hours/week                                 5,271                      1,843                                      34.4                    0.91[\*](#nt114){ref-type="table-fn"}   0.85--0.98                    0.94                    0.86--1.01
  *Comorbidities*                                                                                                                                                                                                                                             
  no CHD                                                                                      14,821                                     5,037                                   33.4                    (reference)                (reference)               
  CHD                                                              4,708                      1,952                                      41.7                    1.42[\*](#nt114){ref-type="table-fn"}   1.32--1.53    1.25[\*](#nt114){ref-type="table-fn"}   1.13--1.39
  no Hyperlipidemia                                                10,035                     3,572                                      35.1                                 (reference)                (reference)                                          
  Hyperlipidemia                                                   9,494                      3,417                                      35.7                                    1.03                    0.97--1.10                    0.97                    0.90--1.05
  no Diabetes mellitus                                             13,757                     4,969                                      35.7                                 (reference)                (reference)                                          
  Diabetes mellitus                                                5,772                      2,020                                      34.7                                    0.96                    0.89--1.02                    0.99                    0.91--1.08
  no Myocardial infarction                                         18,000                     6,242                                      34.2                                 (reference)                (reference)                                          
  Myocardial infarction                                            1,529                       747                                       48.6                    1.82[\*](#nt114){ref-type="table-fn"}   1.63--2.03    1.76[\*](#nt114){ref-type="table-fn"}   1.50--2.05
  no Antihypertensive treatment                                    1,533                       458                                       29.4                                 (reference)                (reference)                                          
  Antihypertensive treatment                                       17,236                     6,296                                      36.2                    1.36[\*](#nt114){ref-type="table-fn"}   1.21--1.53    1.41[\*](#nt114){ref-type="table-fn"}   1.23--1.61

N = 20,164, %w = weighted percentages; OR = Odds Ratio estimated by logistic regression; 95% CI = 95% confidence interval.

unadjusted OR;

adjusted OR from multivariate analyses;

significant on 5% level.

OR for increase of 1 year.

Discussion {#s4}
==========

Prevalence of hypertension was dependent on the definition used, and was lowest for HTN~doc~ and highest for HTN~NHANES~. Comparison of diagnosis and treatment rates and of the proportion with adequate control among patients in the DETECT and HYDRA studies showed only a small improvement in treatment and control rates between 2001 and 2003 and a slight decline in diagnosis rates. The comorbidities of CHD and previous myocardial infarction were associated with pharmacotherapy and adequate blood pressure control, whereas for patients with other comorbidities such as DM and hyperlipidemia control was less likely.

Prevalence of Hypertension {#s4a}
--------------------------

Different definitions of hypertension revealed remarkable differences in prevalence rates. The prevalence rates were lowest for HTN~doc~ and HTN~doc,pat~ and highest for HTN~NHANES~ and HTN~doc,pat,bp~ (56.0% and 55.2%, respectively). This shows that a considerable fraction of people with hypertension had not been diagnosed by physicians. As a consequence treatment and control rates of HTN~NHANES~ based cases are lower in comparison with treatment and control rates based on physician based diagnoses.

Only one study (HYDRA) which is similar to the current one uses the same definitions for hypertension and for the calculation of the prevalence, diagnosis, treatment and control of hypertension [@pone.0052229-Sharma1]. Prevalence rates of hypertension in this study were slightly higher over all groups for HTN~doc~ with 38.8% and slightly lower for HTN~NHANES~ with 50.4%. HTN~doc,pat~ with 39.5% and HTN~doc,pat,bp~ with 52.4% were almost in the same range as in the DETECT study. The total prevalence of hypertension based only on physician's assigned diagnosis should be considered with caution and these results were found in both studies. The degree of underestimation is more pronounced for the younger patients, but is still notable in the older age groups. Our results for the prevalence rate of hypertension are in accordance with a population-based study for Germany (German National Health Interview and Examination Survey 1998) with prevalence rates only slightly lower if applying NHANES definition criteria in this study (53.5% for men and 43.6% for women) [@pone.0052229-Thamm1]. These results suggest that a substantial proportion of people in primary care with hypertension according to NHANES definition criteria are not diagnosed as hypertensive by physicians in Germany.

In a cohort study with original and offspring cohort members of the Framingham Heart Study, the prevalence rate of hypertension according to the NHANES criteria was 27.3% in participants younger than 60 years of age, 63.0% in participants between 60 and 79 years of age and 74.0% in participants above 80 years of age [@pone.0052229-LloydJones1]. These age-specific prevalence rates are lower than for the DETECT study (79.0% for participants between age 60--74 and 86.8% for participants above age 75). One study identified international differences in prevalence, treatment and control rates of hypertension in six different countries (France, Germany, Italy, Spain, UK, US) and used the CardioMonitor Surveys for the year 2004 [@pone.0052229-Wang1]. In that study, the prevalence of hypertension was determined according to the physician's diagnosis, which is identical to our HTN~doc~ definition. Between these six countries there was a range of prevalence rates of hypertension between 78% in UK and 90% in Italy, the prevalence in Germany being 86%. The surprisingly high prevalence rates of hypertension in comparison to the DETECT and HYDRA study can be explained partly by the fact, that these surveys were visit-based and not population-based. Physician sampling was based on a quota criterion -- each physician had a minimum of 15 patients per week with a cardiovascular disease to be included in the respective countries. Sicker patients were oversampled and as a consequence a selection problem with a high proportion of patients with comorbidities existed. The high prevalence rates for hyperlipidemia with 49% and for DM with 29% in the German CardioMonitor survey are in accordance with this interpretation. The prevalence rates in the DETECT study were much lower for hyperlipidemia with 29.5% and for DM with 12.1%.

Diagnosis, Treatment and Control Rates of Hypertension {#s4b}
------------------------------------------------------

On the one hand, there is a decrease in the proportion of patients diagnosed by physicians in the DETECT study in comparison to the HYDRA study. On the other hand, age-specific treatment and control rates were slightly higher. This means that, despite continuous efforts to improve management of hypertension which have included the publication of the HYDRA results, intense continuous medical education (CME) and intensive training programs, there is only a slight improvement of treatment and control and even a decline in the diagnosis rate.

The WHO-Monica-Augsburg study, conducted in 1994/95, has also reported diagnosis, treatment and control rates which have been in a lower range [@pone.0052229-Gasse1]. In contrast to our study, diagnosis of hypertension was defined as reporting a prior diagnosis of hypertension by the participants instead of using the physicians' diagnosis. Diagnosis rate was about 60% for women and 50% for men in 1994/95 and similar to own results in the DETECT study. In comparison with the DETECT study, treatment rates were lower (23% in men and 33% in women) and also control rates were lower (7% in men and 13% in women). Further German studies, for example, the German National Health Interview and Examination Survey in 1998 [@pone.0052229-Janhsen1], have the limitation of using another definition for diagnosis of hypertension (awareness) or the study has only been conducted in certain parts of Germany, as the Study of Health in Pomerania (SHIP) [@pone.0052229-Meisinger1].

Higher control rates of hypertension were reported in the USA compared to those in Germany [@pone.0052229-Burt2], [@pone.0052229-WolfMaier2]. In the Framingham Heart Study treatment rates were 68.9% across the age groups [@pone.0052229-LloydJones1]. Overall, the rates of control were 32.4% in participants with hypertension and 47.0% in treated participants. The estimated sex-specific rate of control was 38% for women and 23% for men.

Factors Associated with Pharmacotherapy {#s4c}
---------------------------------------

DETECT also allowed for the evaluation of the impact of patient characteristics as determinants of pharmacotherapy. Patients with higher age and BMI and comorbidities such as CHD, DM, myocardial infarction, hyperlipidemia showed a higher probability of receiving pharmacotherapy, in agreement with guidelines. These results are partially different from those of the ESTHER study, which is a cohort study conducted in a primary care setting in the German Federal State of Saarland [@pone.0052229-Raum1]. The analyzed sample were hypertensive patients with DM. Similar results for predictors of receiving pharmacotherapy as in the DETECT study were obtained for higher age and BMI, female sex, CHD and current non-smoking. Physical activity and hyperlipidemia had no influence which is in contrast to the DETECT results. A study in the USA of members of the National Health and Human Services Employees Union showed a higher likelihood of receiving pharmacotherapy in participants with a higher age and BMI than in the DETECT and ESTHER study [@pone.0052229-Stockwell1]. Sex had, in contrast to the German studies, no influence.

Factors Associated with Blood Pressure Control {#s4d}
----------------------------------------------

In the DETECT study female sex, a lower BMI, CHD, previous myocardial infarction and antihypertensive medication were associated with adequate blood pressure control. This is in accordance with guideline recommendations that in patients with comorbidities such as CHD or previous myocardial infarction blood pressure control is of high importance. These results are in contrast to the results of the ESTHER study. In this study the only significant negative predictor of an adequate blood pressure in patients with both DM and hypertension was higher age. The difference between DETECT and ESTHER could be explained first by the fact that hypertensive patients with DM are a special subpopulation of hypertensive patients, and second, by choosing a different cut-off point for adequate blood pressure control with a systolic BP of 130 mmHg and a diastolic BP of 85 mmHg in the ESTHER study.

Results for the prediction of adequate blood pressure control in the DETECT study are also in part in agreement with data for hypertensive patients with DM treated in primary care clinics in the USA [@pone.0052229-Duggirala1]. In a retrospective study a higher age was a significant negative predictor for adequate blood pressure control. A history of CHD and also at least one annual visit to a subspecialist had a significant positive influence. In contrast to the results of the DETECT study, no influence of BMI and gender were found and also smoking and physical activity had no influence. Two further studies in the USA estimating control rates had differing results. In the first only female sex and the number of antihypertensive drugs days had a positive significant influence on control of hypertension, whereas higher age, race and a higher BMI played no significant role [@pone.0052229-Stockwell1]. The National Health and Nutrition Examination Survey (NHANES) showed that an age of at least 65 years, male sex, not having visited a physician during the last 12 months had a negative predictive value for an adequate blood pressure control in patients aware of their hypertension [@pone.0052229-Hyman1]. Education, family income and current smoking status had no influence on blood pressure control. Comparing the results from all these studies with the DETECT study shows that a comorbidity such as CHD leads to a higher probability of adequate control, although other potentially remediable factors such as smoking status or physical activity show no association.

As a first limitation of the DETECT study it should be mentioned that blood pressure measurement was only done once, and not repeatedly, under primary care conditions. For a high degree of certainty about diagnosis of hypertension different methods and using the average of several measurements are recommended [@pone.0052229-Powers1]. A single measurement could increase the prevalence of hypertension according to the HTN~NHANES~ definition, because the phenomenon of white coat hypertension could subsequently lead to an underestimation of treatment rates and blood pressure control. In the original study which defined the HTN~NHANES~ criteria for measuring prevalence in the US, two sets of measurements during two different visits had been taken [@pone.0052229-Burt1]. A second limitation of our analysis is the coding of medical diagnoses DM, CHD and hyperlipidemia: it has been based only on a clinical assessment and has not been validated by objective criteria. A third limitation is that a central laboratory was only used in a subset of patients while in other patients values were taken from the patientś records. A fourth limitation is that the time interval between the acquisition of laboratory values and completing the questionnaire was not comparable for all patients, because it was not fixed for all patients. A further limitation was that for estimation of treatment rates of hypertension only pharmacological interventions were considered and no non-pharmacological interventions were taken into account, so that the treatment rates would be higher if non-pharmacological interventions could also have been considered. Estimation of control rates would have been lower if recommended BP values in the guidelines for patients with comorbidities including hyperlipidemia or DM would have been considered.

Conclusions {#s4e}
-----------

Differing definitions of hypertension exist and as a consequence the prevalence rates of hypertension vary accordingly in the DETECT and HYDRA studies. A comparison of the rates of treated and controlled hypertension in the DETECT study with the HYDRA study show indications of small improvements in proportions of patients adequately controlled, although levels of control remain low. With respect to proportions of people diagnosed, there is even a decline. Hypertensive patients with risk factors such as obesity and associated comorbidities such as CHD, hyperlipidemia and DM were more likely to receive antihypertensive drugs in accordance with guidelines. A higher rate of adequate blood pressure control was achieved in patients with obesity and CHD, but not those with DM or hyperlipidemia.

DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment) is a cross-sectional and prospective-longitudinal, nationwide clinical epidemiological study.
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